AQR Capital Management
PLRX icon

AQR Capital Management’s Pliant Therapeutics PLRX Stock Holding History

AQR Capital Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-53,683
Closed -$62.3K – 3557
2025
Q2 		$62.3K Sell
53,683
-18,374
-25% -$26K ﹤0.01% 3226
2025
Q1 		$97.3K Buy
+72,057
New +$437K ﹤0.01% 3017
2023
Q3 		– Sell
-12,434
Closed -$225K – 2364
2023
Q2 		$225K Buy
+12,434
New +$294K ﹤0.01% 2051

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

AQR Capital Management's PLRX Position: Q3 2025 in Review

AQR Capital Management sold out of Pliant Therapeutics (PLRX) in Q3 2025, closing a stake of 53,683 shares — an estimated $62.3K sold.

AQR Capital Management first reported a position in PLRX in Q2 2023 and held it in 3 quarters. The position peaked at $225K in Q2 2023. 99 funds tracked by Wall St. Rank hold PLRX as of Q3 2025.

  • AQR Capital Management reported no remaining Pliant Therapeutics position as of Q3 2025 after selling out during the quarter.
  • AQR Capital Management sold 53,683 Pliant Therapeutics shares in Q3 2025, an estimated $62.3K.
  • AQR Capital Management first reported a position in Pliant Therapeutics in Q2 2023 and held it in 3 quarters.
  • AQR Capital Management's Pliant Therapeutics position peaked at $225K in Q2 2023.
  • 99 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2025.

Based on AQR Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.